BR9709238A - Uso de Il-12 e alfa-interferon para o tratamento de doenças infecciosas - Google Patents

Uso de Il-12 e alfa-interferon para o tratamento de doenças infecciosas

Info

Publication number
BR9709238A
BR9709238A BR9709238A BR9709238A BR9709238A BR 9709238 A BR9709238 A BR 9709238A BR 9709238 A BR9709238 A BR 9709238A BR 9709238 A BR9709238 A BR 9709238A BR 9709238 A BR9709238 A BR 9709238A
Authority
BR
Brazil
Prior art keywords
interferon
alpha
treatment
infectious diseases
infectious
Prior art date
Application number
BR9709238A
Other languages
English (en)
Inventor
Alber Gottfried
Jacqueline Anne Carr
Frank Albert Mattner
Michael John Mulqueen
Kathrin Palmer
Jane Andre Louise Rogerson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9709238A publication Critical patent/BR9709238A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9709238A 1996-05-13 1997-05-07 Uso de Il-12 e alfa-interferon para o tratamento de doenças infecciosas BR9709238A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9609932.0A GB9609932D0 (en) 1996-05-13 1996-05-13 Use of IL-12 and IFN alpha for the treatment of infectious diseases
PCT/EP1997/002336 WO1997042969A1 (en) 1996-05-13 1997-05-07 USE OF IL-12 AND IFN-α FOR THE TREATMENT OF INFECTIOUS DISEASES

Publications (1)

Publication Number Publication Date
BR9709238A true BR9709238A (pt) 1999-08-10

Family

ID=10793602

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709238A BR9709238A (pt) 1996-05-13 1997-05-07 Uso de Il-12 e alfa-interferon para o tratamento de doenças infecciosas

Country Status (14)

Country Link
US (1) US5928636A (pt)
EP (1) EP0907373B1 (pt)
JP (1) JP3246918B2 (pt)
CN (1) CN1178694C (pt)
AR (1) AR007051A1 (pt)
AT (1) ATE270556T1 (pt)
BR (1) BR9709238A (pt)
CA (1) CA2253490C (pt)
DE (1) DE69729796T2 (pt)
ES (1) ES2224246T3 (pt)
GB (1) GB9609932D0 (pt)
PT (1) PT907373E (pt)
TR (1) TR199802329T2 (pt)
WO (1) WO1997042969A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1108050B1 (en) * 1998-08-26 2004-10-06 Heinz Schaller Methods and compositions for expressing heterologous genes in hepatocytes using hepadnaviral vectors
WO2000051631A2 (en) * 1999-03-02 2000-09-08 Schering Corporation Pegylated alpha interferon for hiv therapy
JP2002543144A (ja) * 1999-05-04 2002-12-17 シェーリング コーポレイション ＰＥＧ化インターフェロンαＣＣＲ５アンタゴニスト併用ＨＩＶ療法
US6635646B1 (en) 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
EP1263457A2 (en) * 2000-03-09 2002-12-11 Schering Corporation Hiv immune adjuvant therapy
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1294735A2 (en) 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
WO2002044717A1 (en) * 2000-12-01 2002-06-06 Cornell Research Foundation Animal model for flaviviridae infection
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN100348607C (zh) 2002-06-28 2007-11-14 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒科病毒感染的2’和3’－核苷前药
MXPA04012802A (es) * 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7824851B2 (en) * 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
WO2004052899A2 (en) * 2002-12-12 2004-06-24 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
EP1599171A2 (en) * 2003-02-28 2005-11-30 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
PT1633766T (pt) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
WO2005046746A2 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
US20060018875A1 (en) * 2004-06-14 2006-01-26 Blatt Lawrence M Interferon compositions and methods of use thereof
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
WO2006031725A2 (en) * 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
US7781576B2 (en) * 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EA022952B1 (ru) * 2008-07-23 2016-03-31 Тамара Александровна ВИТКАЛОВА Способ лечения вирусных гепатитов b и c
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CN102309758B (zh) * 2010-07-02 2013-02-20 北京凯因科技股份有限公司 一种治疗肠道病毒感染引起的疾病的药物组合物
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN102512448B (zh) * 2011-12-30 2013-03-27 江苏省疾病预防控制中心 Dc-cik细胞在制备抗hiv感染的药物中的应用
RU2482848C1 (ru) * 2011-12-30 2013-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных с лекарственно-устойчивым туберкулезом и вич-инфекцией
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
WO2019016109A1 (en) * 2017-07-17 2019-01-24 Chu De Nantes - Centre Hospitalier Unversitaire De Nantes INTERLEUKINE 12 (IL12) OR DERIVATIVE THEREOF FOR USE IN THE TREATMENT OF A SECONDARY DISEASE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO164037C (no) * 1980-01-08 1990-08-22 Biogen Inc Fremgangsmaate ved fremstilling av et polypeptid av interferon alfa (ifnalfa)-type.
CH657141A5 (de) * 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
ATE47864T1 (de) * 1984-08-27 1989-11-15 Genentech Inc Verschiedenartige familie von menschlichen leukozyten-interferonen, zusammensetzungen, die diese enthalten, verfahren zu ihrer herstellung, sowie dna und transfektierte wirte hierfuer.
CA2002607C (en) * 1988-11-10 2004-01-27 Gordon G. Wong Natural killer stimulatory factor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
DK0790309T3 (da) * 1989-12-22 2007-11-05 Hoffmann La Roche Cytotoksisk 40kD underenhed af lymfocytmodningsfaktor og monoklonale antistoffer rettet derimod
CA2180193A1 (en) * 1995-06-28 1996-12-29 Edward Baral Enhancing host immunity against viral infections

Also Published As

Publication number Publication date
PT907373E (pt) 2004-10-29
EP0907373B1 (en) 2004-07-07
CA2253490C (en) 2003-02-04
US5928636A (en) 1999-07-27
TR199802329T2 (xx) 2002-12-23
CA2253490A1 (en) 1997-11-20
JP3246918B2 (ja) 2002-01-15
DE69729796D1 (de) 2004-08-12
ES2224246T3 (es) 2005-03-01
DE69729796T2 (de) 2005-07-14
ATE270556T1 (de) 2004-07-15
EP0907373A1 (en) 1999-04-14
AR007051A1 (es) 1999-10-13
JP2000504029A (ja) 2000-04-04
CN1178694C (zh) 2004-12-08
CN1218410A (zh) 1999-06-02
WO1997042969A1 (en) 1997-11-20
GB9609932D0 (en) 1996-07-17

Similar Documents

Publication Publication Date Title
BR9709238A (pt) Uso de Il-12 e alfa-interferon para o tratamento de doenças infecciosas
EE9800382A (et) Lihtherpese viiruse ja teiste nakkushaiguste antimikroobne ravimenetlus
BR9706968A (pt) Uso de antagonistas de alfa-ppar e gama-ppar para o tratamento de sindrome x
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
BR9608758A (pt) Uso de ribavirina e interferom alfa para o tratamento de hepatite c
ATE363904T1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
BR9508886A (pt) Compostos e métodos para o tratamento de câncer
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
BR9307084A (pt) Suporte para cabeça e suporte cirúrgico para cabeça
BR9609532A (pt) Composição antimicrobiana para o tratamento de cabelo processo para o tratamento de caspa e uso da composição
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
DE69504408D1 (de) Antibakterielle Keramik und antibakterieller keramischer Filter
DE4480670T1 (de) Wäßrige Dispersionszusammensetzung und diese nutzende Zusammensetzung
PT928193E (pt) Utilizacao de 1-hidroxi-2-piridonas para o tratamento de infeccoes da pele
DE59707096D1 (de) Haarbehandlungsmittel zur Festigung der Haare
PT983271E (pt) Hemissulfato carbociclico nucleosidico e a sua utilizacao no tratamento de infeccoes virais
BR9606631A (pt) Preparado para o tratamento e condicionamento do cabelo e seu emprego
DE69830259D1 (de) Gewebeschutzmittel und der Gebrauch desselben
FI963263A0 (fi) Bromelaiinin lääkinnällinen käyttö
PT804199E (pt) Uso de penciclovir para o tratamento de nevralgias pos-herpeticas
NO990303L (no) Lipidbindende proteiner og deres terapeutiske og diagnostiske anvendelse
BR9303545A (pt) Procedimento para o tratamento e conformaçao do cabelo
KR960009975U (ko) 일회용 반창고
KR970053437U (ko) 휴대와 사용이 간편한 1회용 풍로
BR9404688A (pt) Composiçao de matéria processo para o tratamento de doenças virais e tumorais e uso da composiçao

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09S Decision of refusal: publication cancelled [chapter 9.2.2 patent gazette]

Free format text: ANULADA A PUBLICACAO DE INDEFERIMENTO POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]